TB-500 (Thymosin Beta-4 fragment)
In short
Researched for how it may help your body heal from injuries faster by repairing damaged muscles, tendons, and tissues.
Overview
TB-500 is a synthetic 7-amino acid fragment (Ac-LKKTETQ) corresponding to the active actin-binding region (positions 17-23) of thymosin beta-4. Originally developed for veterinary use in horses, this fragment retains tissue repair and anti-inflammatory properties while being more stable than the full peptide. Banned by WADA for its performance-enhancing effects
Injectable TB-500 provides systemic distribution for whole-body tissue repair. Acts as the principal actin-sequestering protein, regulating cell migration, promoting angiogenesis, reducing inflammation, and activating stem cell differentiation for accelerated healing.
Molecular information
First-order decay curve at 60.0h half-life from literature. Educational only.
Research indications
Grouped by area. Each entry reflects a separate published hypothesis or clinical signal - not medical advice.
G-actin sequestration accelerates migration of myoblasts and fibroblasts into injury zone. In quadriceps contusion models shortens time to full recovery by 30-40%.
Transient fatigue 2-12 hours post-dose
common
Injection-site reaction
common
Headache (dose-dependent)
uncommon
7 peer-reviewed sources
References
Links to peer-reviewed publications on PubMed, cited in the peptide's scientific profile.
Smart et al. — Cardiac progenitor activation
Animal study | 150 mg/kg i.p. | 4 weeks | Activation of epicardium-derived cells + 50% revascularization
Nature · 2007
View the studyBock-Marquette — Tβ4 cardioprotection
Animal study | 150 mcg s.c. | 14 days | Improved LV function post-MI by 50% vs control
Nature · 2004
View the studyInformation about TB-500 is based on published scientific research and is intended for research purposes only. Not medical advice.
Products are for in vitro laboratory research only. Not approved for human consumption.
Other peptides
5-Amino-1MQ
5-Amino-1MQ is a small-molecule selective inhibitor of NNMT (nicotinamide N-methyltransferase), identified by Anthony Sauve (Cornell) in 2018. NNMT is a "metabolic sink" for methyl donors and NAD+ — suppressing it in adipocytes raises energy expenditure without reducing calorie intake.
ReadAdipotide
Adipotide is a target peptide developed by Wadih Arap and Renata Pasqualini (MD Anderson) for selective elimination of white adipose tissue. It binds prohibitin on adipocyte vasculature and induces apoptosis of the blood vessels supplying fat tissue — leading to nonsurgical fat reduction.
ReadAOD-9604
AOD-9604 is a modified C-terminal 16-amino-acid fragment of human growth hormone (177-191), supplemented with a tyrosine residue. Retains the lipolytic effect of the full molecule but without diabetogenic or GH-stimulating activity. Developed by Metabolic Pharmaceuticals (Australia) in the 1990s.
ReadARA-290
ARA-290 (Cibinetide) is an 11-amino-acid fragment of erythropoietin (EPO) developed by Anthony Cerami as a cytoprotective molecule without erythropoietic activity. It retains the tissue-protective effects of EPO without raising hematocrit — explaining its potential in diabetic neuropathy and cardiac applications.
ReadArgireline
Argireline is a synthetic acetylated hexapeptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) derived from SNAP-25 — the SNARE complex subunit mediating acetylcholine release at neuromuscular junctions. Topical application reduces muscle activity in expression areas — which is why Argireline is marketed as a "topical Botox alternative".
ReadBPC-157
BPC-157 is a 15-amino-acid fragment isolated from a protective protein in human gastric juice — hence the name Body Protection Compound. Over thirty years of research by Predrag Sikiric's group at the University of Zagreb (100+ peer-reviewed papers) establish its angiogenic action through the VEGFR2 receptor and its stimulation of fibroblasts. If you work with in vitro models of tendon, muscle or gut tissue, BPC-157 is among the most extensively documented regenerative peptides.
ReadEducation
No comments yet. Be the first.
Comments are reviewed before publishing.
